Trial Profile
Multicenter randomized controlled phase 2 trial to evaluate AM-125 in the treatment of acute peripheral vertigo following neurosurgery (TRAVERS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Betahistine (Primary) ; Betahistine
- Indications Vertigo
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms TRAVERS
- Sponsors Altamira Therapeutics
- 01 Jun 2023 Results assessing the safety and efficacy of AM-125 nasal spray (intranasal betahistine) in the treatment of surgery-induced acute vestibular syndrome, published in the Otology and Neurotology.
- 19 Dec 2022 This trial has been completed in Slovakia, Belgium, and Poland (Date of the global end of the trial : 28-Mar-2022), according to European Clinical Trials Database record.
- 30 Aug 2022 According to an Altamira Therapeutics media release, the study team has been drafting an article for publication in a scientific journal.